Jim Hoffman: Timely Extracorporeal NET Removal Therapy Should Be Tried on High-Risk Patients
Jim Hoffman, Technical Advisor at Cygnus Technologies, LLC, reposted from Jocelyn M. on LinkedIn:
“We very likely should be adding this simple rapid test to the ASCVD risk assessment, given the evidence of elevated NETosis induction, impaired NET clearance, and the participation of NETs in clotting abnormalities, structural fibrinolytic-resistant microthrombi, and larger vessel ischemic atheroma formation. Timely extracorporeal NET removal therapy should be tried on high-risk patients.
NETosis contributes to immunothrombosis from multiple infectious and non-infectious disease triggers, which contribute to vasculitis and compromise microcirculatory perfusion. Worse yet, impaired NETs clearance physically participates in life-threatening prothrombotic ischemic events, DVTs, PEs, MI, strokes and is a prime risk marker for DIC and circulatory collapse as previously demonstrated by Toh et al. For more research on dysregulated NETosis and CVD risk, visit here.″
Quoting Jocelyn M.’s post:
“We do need to do better and it is possible. In the US, heart attack risk is typically assessed according to a set of criteria such as an atherosclerotic cardiovascular disease (ASCVD) score, which measures factors linked to the development of cardiovascular disease. Patients are then monitored or treated if their scores exceed a certain threshold.
Researchers from the US and Canada gathered the health records of 465 people 65 years or younger who had been treated for their first heart attack between January 2020 and July 2025 at one of two US medical centers. The data included details such as medical history, blood pressure, and cholesterol levels.,
Based on the team’s analysis, two days before their heart attack, ASCVD scores would have categorized 45 percent of the patients at low or borderline risk levels. An alternative set of criteria, called a predicting risk of cardiovascular disease events (PREVENT) score, fared even worse: 61 percent of the patients would have been classified as low or borderline risk.”
Title: Nearly Half of All Heart Attacks May Be Missed by Current Screening Tools
Authors: David Nield
For more information, here.
Read full paper here.
Stay informed with Hemostasis Today.
-
May 6, 2026, 11:14Li Khim Kwah: Proud for the Development of The New Singapore Stroke Rehabilitation Guideline
-
May 6, 2026, 10:55Hugo Antonio Romo Rubio: A New Paradigm in Treatment for Hemophilia A from FRONTIERS2 Phase 3 Study
-
May 6, 2026, 10:40Ifeanyichukwu Ifechidere: Why INR Can Be Dangerously Misleading
-
May 6, 2026, 02:58Limiaa Babikir: What Is Polyspecific DAT?
-
May 6, 2026, 02:47Karen Rollinson: Connecting with so Many Families and Advocates at HFA 2026
-
May 6, 2026, 02:38Moustafa Abdou: Is the Bone Marrow Examination Still the ‘Gold Standard’?
-
May 6, 2026, 02:23Khaled Musallam: When the Worlds of Thalassemia and Hemophilia Converge
-
May 6, 2026, 02:12Caitlin Raymond: How STOP-BABESIOSIS Just Rewrote 40 Years of Practice
-
May 5, 2026, 16:28Nikolay Novitski: A New Era in Cardiovascular Prevention